Patient recruitment

NOXXON Pharma: Data Safety Monitoring Board Confirms Safety and Validates Recruitment of Last Patients in Final High-Dose Cohort of NOX-A12 in Phase 1/2 Brain Cancer Study

Retrieved on: 
Friday, March 12, 2021
Biotechnology, Health, Pharmaceutical, Clinical trials, Oncology, Health sciences, Pharmaceutical industry, Health, Medicine, Medical physics, Clinical pharmacology, Clinical research, Clinical trial, Brain tumor, Radiation therapy, Patient recruitment, Cancer and Leukemia Group B

The DSMB concluded that it is safe and appropriate to continue patient recruitment according to the study protocol.

Key Points: 
  • The DSMB concluded that it is safe and appropriate to continue patient recruitment according to the study protocol.
  • The Phase 1/2 clinical study is testing three dose regimens of NOX-A12 (200, 400 and 600 mg/week), each combined with external-beam radiotherapy, in newly diagnosed brain cancer patients.
  • Based on the DSMBs confirmation, participating clinical centers have now initiated final patient recruitment for the last and highest dose group.
  • The outcome of this meeting will inform the recommended dose for the next randomized, controlled brain cancer trial which will lead to the registration of NOX-A12.

Creative Medical Technology Holdings, Inc. Begins Recruitment of StemSpine® Clinical Sites

Retrieved on: 
Wednesday, March 10, 2021
Clinical trials, Advertising, Patient recruitment, Pharmaceutical industry, Recruitment

PHOENIX, March 10, 2021 /PRNewswire/ -- Creative Medical Technology Holdings, Inc. (OTC: CELZ), a leading commercial stage biotechnology company focused on a regenerative approach to Immunotherapy, Urology, Neurology and Orthopedics, today announced that it has started recruitment of clinical sites for StemSpine.

Key Points: 
  • PHOENIX, March 10, 2021 /PRNewswire/ -- Creative Medical Technology Holdings, Inc. (OTC: CELZ), a leading commercial stage biotechnology company focused on a regenerative approach to Immunotherapy, Urology, Neurology and Orthopedics, today announced that it has started recruitment of clinical sites for StemSpine.
  • Patient recruitment will begin immediately upon signing of the first clinical site.
  • See the periodic and other reports filed by Creative Medical Technology Holdings, Inc. with the Securities and Exchange Commission and available on the Commission's website at www.sec.gov .
  • View original content to download multimedia: http://www.prnewswire.com/news-releases/creative-medical-technology-hold...
    SOURCE Creative Medical Technology Holdings, Inc.

TrialJectory Achieves 500 Percent Year-Over-Year Growth as Cancer Patients and Pharmaceutical Industry Increasingly Leverage Proprietary AI Platform in COVID-19 Pandemic

Retrieved on: 
Tuesday, March 9, 2021
Health sciences, Health, Pharmaceutical industry, Clinical pharmacology, Clinical research, Clinical trial, Design of experiments, Food and Drug Administration, Patient recruitment, Cancer and Leukemia Group B

Over the same period, TrialJectory experienced a significant increase in strategic collaborations with pharmaceutical companies and contract research organizations (CROs).

Key Points: 
  • Over the same period, TrialJectory experienced a significant increase in strategic collaborations with pharmaceutical companies and contract research organizations (CROs).
  • "The demand from cancer patients for increased access to information and participation in clinical trials started before the pandemic.
  • More patients will turn to TrialJectory as their trusted partner to ensure they receive the most appropriate, effective treatment options available.
  • "In a very short period of time, TrialJectory has successfully positioned itself as the go-to resource for cancer patients and the pharmaceutical industry.

Building A Successful Clinical Trial Engagement Platform, Upcoming Webinar Hosted by Xtalks

Retrieved on: 
Wednesday, February 17, 2021
Pharmaceutical industry, Health sciences, Health, Clinical trials, Medical research, Clinical research, Design of experiments, Patient recruitment

This webinar will illustrate why a clinical trial engagement platform is a critical asset for sponsors.

Key Points: 
  • This webinar will illustrate why a clinical trial engagement platform is a critical asset for sponsors.
  • These areas of content and, importantly, acknowledgment of patients' health literacy levels, are vital to making your Clinical Trial Engagement Platform successful and will be shared throughout this webinar.
  • Why is a clinical trial engagement platform important, and how can you develop a successful one?
  • The panelists include:
    Kelly White, Head of Global Trial Optimization: Oncology, Merck
    Sara Pierson, Director of Patient Recruitment Programs, Pfizer
    Gwenn Oakes, Associate Director of Global Trial Optimization, Merck
    For more information, or to register for this event, visit Building A Successful Clinical Trial Engagement Platform.

ObvioHealth Announces Next Generation Virtual Research Platform and Ecosystem

Retrieved on: 
Tuesday, February 16, 2021
Health sciences, Health, Pharmaceutical industry, Clinical pharmacology, Clinical research, Clinical trials, Patient recruitment, Recruitment, Adherence, VRO, Remote patient monitoring

NEW YORK, Feb. 16, 2021 /PRNewswire/ -- ObvioHealth, a global Virtual Research Organization (VRO), announces its next generation platform offering enhanced remote patient monitoring capabilities for the company's end-to-end decentralized clinical trial solutions.

Key Points: 
  • NEW YORK, Feb. 16, 2021 /PRNewswire/ -- ObvioHealth, a global Virtual Research Organization (VRO), announces its next generation platform offering enhanced remote patient monitoring capabilities for the company's end-to-end decentralized clinical trial solutions.
  • To date, dozens of ObvioHealth virtual trials have delivered best in class metrics for patient recruitment time, medication adherence and retention.
  • The platform upgrade builds on this momentum, integrating an ecosystem of FDA-cleared devices to support remote monitoring through seamless connections to its patient-centric app.
  • ObvioHealth is an end-to-endVirtual Research Organization (VRO) that delivers better data to sponsors and an easier clinical trial experience for participants.

Joint Study Shows Decentralized Clinical Trials More Resilient than Traditional Trials During Global Pandemic

Retrieved on: 
Thursday, February 11, 2021
Pharmaceutical industry, Health sciences, Clinical research, Clinical trials, Health, Medical research, Design of experiments, Patient recruitment

CARY, N.C.and NEW YORK, Feb. 11, 2021 /PRNewswire/ -- THREAD , a global decentralized clinical trials (DCTs) and eCOA provider, and Lokavant ,a leading clinical trial intelligence company, today announced the results of a joint analysis demonstrating that clinical trials using decentralized approaches during the COVID-19 pandemic outperformed traditional trials in patient recruitment and retention levels.

Key Points: 
  • CARY, N.C.and NEW YORK, Feb. 11, 2021 /PRNewswire/ -- THREAD , a global decentralized clinical trials (DCTs) and eCOA provider, and Lokavant ,a leading clinical trial intelligence company, today announced the results of a joint analysis demonstrating that clinical trials using decentralized approaches during the COVID-19 pandemic outperformed traditional trials in patient recruitment and retention levels.
  • However, decentralized trials rapidly returned to pre-pandemic recruitment and retention levels while traditionally designed clinical trials had yet to recover through September 2020.
  • Traditional clinical trials had greater difficulty doing so, in part because trial protocols, study technologies, and schedule of event designs precluded the adoption of decentralized approaches.
  • "Though the industry clearly understands the value, practicality, and promise of decentralized trials, it's important for us to study, quantify, and report how these approaches positively impact clinical trials."

TMG360 Media Announces Appointment of Kayleen M. Brown as Vice President

Retrieved on: 
Thursday, February 4, 2021
Marketing, Advertising, Patient recruitment, Pharmaceutical industry, Recruitment, Digital marketing, Medtech

SAN FRANCISCO, Feb. 4, 2021 /PRNewswire/ --Kayleen M. Brown has been appointed Vice President of TMG360 Media, the new digital platform created to drive brand awareness, patient recruitment, strategic partnerships and funding access in the healthtech industry.

Key Points: 
  • SAN FRANCISCO, Feb. 4, 2021 /PRNewswire/ --Kayleen M. Brown has been appointed Vice President of TMG360 Media, the new digital platform created to drive brand awareness, patient recruitment, strategic partnerships and funding access in the healthtech industry.
  • In her new role, Brown will manage the TMG360 newsroom and the team of healthtech journalists, covering market and industry trends, product launches and government affairs.
  • TMG360 Media is a partnership between The Mullings Group, a leading medtech talent-acquisition firm, and Lobeline Communications, a leading digital media and PR firm in Los Angeles.
  • TMG360 Media is a communications, design and digital marketingplatform, created to bring healthtech companies to market faster.

Trialbee Announces the Release of HIVE, the Smartest Way to Leverage Real-World Data in Patient Recruitment

Retrieved on: 
Tuesday, February 2, 2021
Other Health, Software, Research, Pharmaceutical, Data management, Technology, Hospitals, Clinical trials, Science, Nanotechnology, Practice Management, Health, Health sciences, Life sciences, Health, Clinical research, Clinical trials, Pharmaceutical industry, Clinical data management, Clinical trial management system, Patient recruitment, High-performance Integrated Virtual Environment, ERT, RWD

Traditional patient recruitment has limited access to patients and takes a long time to accomplish.

Key Points: 
  • Traditional patient recruitment has limited access to patients and takes a long time to accomplish.
  • Trialbee HIVE is a result of combined expertise and close collaboration with Trialbee partner organizations specializing in global health research networks, RWD management, advanced data science techniques, consumer data connectivity platforms and eClinical technologies.
  • For more information on how HIVE can improve your trials patient recruitment and engagement, visit https://trialbee.com/platform/hive/ to schedule a demo .
  • Trialbee is a world leading technology provider in patient matching and engagement, empowering patients to participate in clinical trials as a care option.

BIOPHYTIS receives DMC recommendation for starting recruitment for Part 2 of its Phase 2-3 COVA study in COVID-19

Retrieved on: 
Tuesday, January 19, 2021
Articles, Ethics, Academic disciplines, Clinical trials, Pharmaceutical industry, Design of experiments, Advertising, Patient recruitment, Recruitment, Institutional review board, Coronavirus disease

The COVA Study assesses Sarconeos (BIO101) as a potential treatment for acute respiratory failure associated with COVID-19.

Key Points: 
  • The COVA Study assesses Sarconeos (BIO101) as a potential treatment for acute respiratory failure associated with COVID-19.
  • The DMCs recommendation is based on its review of the safety data analysis from the first 20 patients enrolled in the study.
  • Based on the DMCs recommendation,BIOPHYTIS intends to start patient recruitment for Part 2 of the COVA Study in countries where applicable regulatory approvals or permissions, including Institutional Review Board/Ethics Committee approvals, are obtained.
  • Stanislas Veillet, Chief Executive Officer of BIOPHYTIS, said: We are extremely pleased to receive the DMCs recommendation to commence recruitment for Part 2 of the COVA Study.

Beyond Celiac Celebrates Record Accomplishments in 2020

Retrieved on: 
Thursday, January 14, 2021
Health sciences, Health, Pharmaceutical industry, Medical specialties, Autoimmune diseases, Celiac, Patient recruitment, Clinical trial, Sjögren syndrome, Draft:Beyond Celiac

Philadelphia, PA, Jan. 14, 2021 (GLOBE NEWSWIRE) -- Beyond Celiac , the leading catalyst for a celiac disease cure in the United States, partnered with a record number of key biotechnology and pharmaceutical companies in 2020 to recruit patients for clinical trials of promising treatments for celiac disease.

Key Points: 
  • Philadelphia, PA, Jan. 14, 2021 (GLOBE NEWSWIRE) -- Beyond Celiac , the leading catalyst for a celiac disease cure in the United States, partnered with a record number of key biotechnology and pharmaceutical companies in 2020 to recruit patients for clinical trials of promising treatments for celiac disease.
  • The organization continued to be a vital bridge between the celiac disease community and researchers to power progress.
  • Recent partnerships include:
    Exclusive recruitment partner for the 9 Meters Biopharma study of larozotide acetate, which aims to address leaky gut in celiac disease.
  • Patient recruitment efforts are led by the unrivaled ability Beyond Celiac has to reach celiac disease patients who are interested in participating in clinical trials.